Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478514 | 1.00 | HSD11B1 (0.57) | HSD11B1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5476449 | 0.93 | MEN1 (0.55) | HSD11B1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5476452 | 0.93 | MEN1 (0.55) | HSD11B1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL228921 | 0.92 | HSD11B1 (0.63) | HSD11B1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL21381625 | 0.89 | HSD11B1 (0.48) | HSD11B1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL1991541 | 0.87 | KMT2A (0.52) | HSD11B1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1991537 | 0.87 | KMT2A (0.52) | HSD11B1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL29537844 | 0.87 | KMT2A (0.52) | HSD11B1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL21848120 | 0.87 | KDM4E (0.56) | KMT2AMEN1KDM4E | |
| SCHEMBL407900 | 0.87 | KDM4E (0.56) | KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | claimed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| EP-1517894-B1 | N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-09-06 | — | — | EP | disclosed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885ALDH1A1 76/4885LMNA 3054/4885 |
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | HTR7, OPRL1, HCRTR1 | HSD11B1 1006/4885ALDH1A1 2980/4885LMNA 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.